Search results
Psoriasis: Features That May Affect Biologic Rx Outcomes
Medscape· 3 days agoSeveral clinical characteristics were negatively associated with responses to biologics in a...
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the ...
Morningstar· 16 hours ago(NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of TREMFYA ...
In a 'gold rush' for treating bowel disease, AbbVie clears one more stage
Crain s Chicago Business· 2 days agoWith the arrival of biosimilar competition for its blockbuster drug Humira, AbbVie has said much of its sales growth potential lies with these two anti-inflammatories. In ...
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis
Zacks via Yahoo Finance· 2 days agoIn addition, immune system irregularities, higher diagnosis rates, increased focus on early...
FDA Approves Skyrizi for Ulcerative Colitis
Medscape· 2 days agoThe approval is the fourth indication for the anti–interleukin 23 monoclonal antibody after approval for Crohn's disease, psoriatic arthritis, and plaque...
Drug names: How companies and regulators come up with hundreds of new names every year
Quartz· 2 days agoEverything you need to know about the art and science of drug naming in five minutes or less,...
AbbVie stock price forecast: $200 on the cards? | Invezz
Invezz· 23 hours agoSupported by robust data from two Phase 3 clinical trials, INSPIRE and...Skyrizi’s potential to become a cornerstone therapy in AbbVie’s portfolio, particularly as a successor to its blockbuster ...
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio...
FOX 23 News Albany· 3 days agoApproval supported by two Phase 3 clinical trials that evaluated SKYRIZI® for the treatment of moderate to severe ulcerative colitis: a 12-week induction study, INSPIRE,1 ...
Gateway - Quartz
Quartz· 3 days agoEvery pharmaceutical company is constantly searching for its next blockbuster — the billion-dollar drug that dominates a market, brings in hordes of customers, and deposits ...
First Financial Bank Trust Division Has $345,000 Position in Amgen Inc. (NASDAQ:AMGN)
ETF DAILY NEWS· 2 days agoFirst Financial Bank Trust Division lowered its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 15.2% during the first quarter, according to the company in its most recent Form 13F filing ...
